Compound News and Research

RSS

ChanTest to provide new system for LGIC and VGIC screening

Beginning next month, ChanTest Corporation will offer the highest throughput electrophysiology platform on the market validated for both voltage-gated and rapidly desensitizing ligand-gated ion channels.

7 Apr 2011

Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting

Aeterna Zentaris Inc. today announced that a poster on its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131, was presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

6 Apr 2011

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

Researchers from Boston University School of Medicine, including Yu Li, PhD, and other colleagues, have demonstrated that a nutrient sensing pathway is involved in the disruption of cellular lipid homeostasis in obese and insulin resistant mice fed a diet high in fat and sucrose.

6 Apr 2011

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today presented results of preclinical studies on its novel Phosphoinositide 3-kinase alpha inhibitor at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

6 Apr 2011

La Jolla acquires GliaMed's novel class of compounds

La Jolla Pharmaceutical Company today announced that it has acquired the rights to a novel class of compounds known as Regenerative Immunophilin Ligands from privately held GliaMed, Inc.

5 Apr 2011

NIPH study finds NDMA as one of the most carcinogenic compounds formed during CO2 capture

CO2 capture by means of amines is considered to be the most appropriate method to quickly begin with CO2 removal. During this capture process, some of the amines escaping the recycling process will be emitted into the air and will also form other compounds such as nitrosamines and nitramines.

5 Apr 2011

Study finds substantial increase in pediatric CT in hospital emergency departments

Computed tomography examinations of children in hospital emergency departments increased substantially from 1995 to 2008, according to a new study published online and in the June print edition of Radiology. Researchers said the findings underscore the need for collaboration among medical professionals to ensure that pediatric CT is appropriately ordered, performed and interpreted.

5 Apr 2011

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

OncoGenex Pharmaceuticals, Inc. announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Artemisinin or high-pressure oxygen can boost natural cancer remedy

A technique Michael Jackson reportedly used to prolong his youth is showing promise as a way to boost the effectiveness of a natural cancer remedy.

5 Apr 2011

Heavy beer drinkers with specific genetic variant at increased risk of non-cardia gastric cancer

Heavy beer drinkers who have a specific genetic variant in the cluster of three genes that metabolize alcohol are at significantly higher risk of developing non-cardia gastric cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Eli Lilly and Company announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.

5 Apr 2011

Scientists discover new compounds that may help fight against parasitic diseases

Trypanosomatid parasites cause diseases like African sleeping sickness, Chagas' disease and leishmaniasis. Leishmaniasis affects about 12 million people worldwide, mostly in developing countries. Current drug treatments are inadequate due to drug toxicity and resistance.

5 Apr 2011

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.

5 Apr 2011

Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer Inc. announced today that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for tafamidis, the company's novel, oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).

4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

Compound News and Research

ChanTest to provide new system for LGIC and VGIC screening

Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

La Jolla acquires GliaMed's novel class of compounds

NIPH study finds NDMA as one of the most carcinogenic compounds formed during CO2 capture

Study finds substantial increase in pediatric CT in hospital emergency departments

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Artemisinin or high-pressure oxygen can boost natural cancer remedy

Heavy beer drinkers with specific genetic variant at increased risk of non-cardia gastric cancer

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Scientists discover new compounds that may help fight against parasitic diseases

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News